DOCSLIB.ORG

Blueprint of Pediatric Endocrinology Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/317428263 blueprint of pediatric endocrinology book Book · January 2014 CITATIONS READS 0 27 1 author: Abdulmoein Eid Al - Agha King Abdulaziz University 148 PUBLICATIONS 123 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: HYPOPHOSPHATEMIC RICKETS, EPIDERMAL NEVUS SYNDROME WITH... View project HYPERTRIGLYCERIDAEMIA-INDUCED ACUTE PANCREATITIS IN AN INFANT: A CASE REPORT View project All content following this page was uploaded by Abdulmoein Eid Al - Agha on 09 June 2017. The user has requested enhancement of the downloaded file. IN THE NAME OF ALLAH, THE MERCIFUL, THE MERCY-GIVING iii Blueprint in Pediatric Endocrinology Abdulmoein Eid Al-Agha, MBBS, DCH, FRCPCH Pediatric Endocrinologist King AbdulAziz University Faculty of Medicine Jeddah, Saudi Arabia © King Abdulaziz University: 1435 A.H. (2014 AD.) All rights reserved. 1st Edition: 1435 A.H. (2014 A.D.) Table of Contents Chapter 1: Basic Endocrinology Introduction…………………………………………………………………….. 3 Effects of hormones…………………………………………………………….. 3 Types of hormones……………………………………………………………… 4 Types of Hormone Receptors………………...………………………………... 5 Loss – of – function mutations………………………………………………….. 7 Gain – of – function mutations……………………………...………………….. 9 Fetal Brain Programming ………………………………………………………. 10 The endocrine system ……………………………...…………………………... 10 Hypothalamic-Pituitary Relationships………………………………………….. 10 Hypothalamic Controls…………………………………………………………. 11 Anterior Pituitary Function……………………………………………………... 11 Posterior Pituitary Function…………………………………………………….. 13 Chapter 2: Disorders of Calcium and Bone Metabolism Introduction…………………………………………………………..…………. 17 Vitamin D ………………………………………………………………………. 18 Parathyroid glands…………………………………………………...…………. 19 Calcitonin……………………………………………………………………….. 20 The calcium-sensing receptor (CaSR)………………………………………….. 21 Parathyroid Hormone–Related Peptide (PTHrP)……………………………….. 21 Hypocalcaemia………………………………………………………………….. 22 Hypocalcaemia in neonates……………………………………………………... 22 Hypocalcaemia in infants & children…………………………...……………… 23 Clinical manifestations of Hypocalcaemia…………………...………………… 24 Investigations of Hypocalcaemia……………………………………………….. 25 Rickets and Osteomalacia………………………………………………………. 28 Causes of Rickets ………………………………………………………………. 29 Vitamin D–dependent rickets (type I)…………………………………………... 35 v vi Blueprint in Pediatric Endocrinology Vitamin D-resistant rickets (type II vitamin D–dependent rickets) ……………. 35 Hypophosphatemic Rickets…………………………………………………….. 37 Hypophosphatasia ……………………………………………………………… 37 Treatment of Hypophosphatasia ……………………………………………….. 38 Drug-induced rickets……………………………………………………………. 39 Fanconi's syndrome …………………………………………………………….. 40 McCune-Albright syndrome……………………………………………………. 40 Renal Osteodystrophy (Renal Rickets)…………………………………………. 41 Hepatic Rickets…………………………………………………………………. 41 Malabsorption & Rickets……………………………………………………….. 41 Oncogenic Osteomalacia……………………………………………………….. 42 Hypoparathyroidism……………………………………………………………. 43 Pseudohypoparathyroidism (PHP)……………………………………………… 49 Pseudopseudohypoparathyroidism …………………………………………….. 51 Treatment of Pseudopseudohypoparathyroidism ………………………………. 54 Hypomagnesaemia……………………………………………………………… 54 Hypercalcemia in children……………………………………………………… 55 Oncogenic Hypercalcemia……………………………………………………… 59 Clinical manifestations of hypercalcemia………………………………………. 59 Treatment of Oncogenic Hypercalcemia……………………………………….. 60 Osteoporosis in children and adolescence……………………………………… 63 Primary osteoporosis……………………………………………………………. 64 Osteogenesis imperfecta (OI)…………………………………………………... 65 Idiopathic juvenile osteoporosis ……………………………………………...... 67 Secondary osteoporosis…………………………………………………………. 67 Chapter 3: Disorders of sex development Classification of disorders of sexual development……………………….....…… 80 Stages of sexual differentiation…………………………………………………. 80 Sex differentiation in embryo and fetus………………………………………… 80 Gonadal differentiation…………………………………………………………. 81 Causes of abnormal sexual differentiation……………………………………… 85 Table of Contents vii Congenital Adrenal hyperplasia (CAH)………………………………………… 85 Maternal androgens …………………………………………………………….. 89 Aromatase enzyme deficiency………………………………………………….. 89 XX Male Syndrome ……………………………………………………………. 90 Persistent Müllerian Duct Syndrome (PMDS)……………….………………… 90 Gonadotrophin deficiency causing DSD……………………………………….. 91 Leydig cell agenesis ………………………………………………….………… 91 Testosterone biosynthesis defects………………………………………………. 91 Androgen Insensitivity Syndrome (AIS) ………………………….…………… 92 5-alpha-reductase type 2 deficiency ……………………………….…………… 93 Ovotesticular disorders of sexual development (formerly true hermaphroditism) 93 …………………………………………………………… Partial gonadal dysgenesis……………………………………………………… 94 Pure gonadal dysgenesis………………………………………………………... 95 XY Female Syndrome …………………………………………………………. 95 Diagnosis of CAH……………………………………………………….……… 96 Medical management of CAH………………………………………………...... 98 Considerations for sex assignment in CAH………………...…………………... 99 Dysmorphic syndromes with DSD……………………………………………... 101 Micropenis……………………………………………………………………… 105 Hypospadias ……………………………………………………………………. 110 Cryptorchidism………………………………………………………………..... 110 Retractile testicle(s)…………………………………………………………….. 114 Chapter 4: Reproductive Disorders Normal pubertal development………………………………………..………… 117 Physiology of Puberty……………………………...…………………………… 118 Puberty onset…………………………………………………...……………….. 121 Physical changes in boys during Puberty……………………………………...... 122 Physical changes in girls during pubrty………………………………………… 124 Precocious Puberty……………………………………………………………… 126 Sequelae of precocious puberty………………………………………………… 127 Causes of central (GnRH dependent)…………………………………………... 128 viii Blueprint in Pediatric Endocrinology Environmental & genetic factors influencing HPG axis activation………..…... 128 Peripheral precocious puberty…………………………………...……………… 129 McCune-Albright Syndrome (MAS)………………………………...…………. 131 Variation of normal pubertal development…………………………...………… 133 Premature pubarche ………………………………………………...………….. 134 Premature Thelarche ………………………………………………...…………. 134 Growth hormone (GH)………………………………………………...………... 137 Cyproterone acetate (Androcur)………………………………………..………. 139 Medroxyprogestrone acetate (Depo-Provera)…………………………...……… 140 GnRH antagonist…………………………………………………………...…… 140 Treatment of peripheral precocious puberty………………………………...….. 142 Complications of peripheral precocious puberty……………………………...... 145 Delayed puberty………………………………………………………………… 145 Hypogonadotropic hypogonadism……………………………………………… 146 Constitutional Delay of Growth and Puberty (CDGP)…………………………. 149 Hypothalamic-pituitary disorders………………………………………………. 149 Hypergonadotrophic hypogonadism……………………………………………. 150 Turner's syndrome ……………………………………………………………… 151 Klinefelter's syndrome …………………………………………………………. 152 Pubertal induction………………………………………………………………. 155 Polycystic Ovarian Syndrome (PCOS)…………………………………………. 156 Hirsutism……………………………………………………………………….. 160 Ferriman-Gallwey score for hirsutism…………………………………...…….. 161 Gynecomastia…………………………………………………………………… 165 Causes of elevated estrogen levels or activity………………………………….. 167 Causes of testosterone deficiency………………………………………………. 167 Causes of impaired testosterone action…………………………………………. 168 Chapter 5: Thyroid disorders in children The Thyroid Gland……………………………………………………………… 173 The Placenta and the Thyroid Gland…………………………………………… 174 Physiology the Thyroid Gland………………………………………………..... 175 Table of Contents ix Thyroid hormone synthesis…………………………………………………….. 176 Congenital Hypothyroidism (CH)……………………………………………… 177 Causes of permanent congenital hypothyroidism ……………………………… 178 Diagnostic tests in thyroiditis…………………………………………………… 178 Treatment of thyroiditis………………………………………………………… 186 Drugs or goitrogens…………………………………………………………….. 187 Secondary or tertiary hypothyroidism………………………………………….. 187 Thyroid hormone resistance…………………………………………………..... 187 Clinical manifestations of acquired hypothyroidism…………………………… 188 Average daily doses of L-Thyroxin…………………………………………..... 190 Hyperthyroidism……………………………………………………………….. 190 Transient neonatal hyperthyroidism……………………………………………. 190 Clinical manifestations of hyperthyroidism…………………………………..... 191 Neonatal thyrotoxicosis………………………………………………………… 192 Permanent neonatal hyperthyroidism…………………………………………… 193 Chapter 6: Growth and Growth Disorders Hormonal influences on fetal growth ………………………..………………… 209 Factors determining normal growth depend on the child's age………………… 209 Growth assessment……………………………………………………………… 210 Short stature…………………………………………………………………...... 212 Causes of short stature………………………………………………………...... 213 SHOX deficiency syndromes …………………………………………………... 218 Malnutrition…………………………………………………………………….. 220 Malabsorption / Gastrointestinal Diseases……………………………………… 220 Syndromes associated with short stature……………………………………….. 221 Congenital GH deficiency………………………………………………………. 229 Hypothalamic–Pituitary Malformations………………………………………... 229 Hereditary GH Deficiency……………………………………………………… 230 GH1 gene……………………………………………………………………...... 231 GHRH Receptor………………………………………………………………… 231 Congenital structural CNS defects …………………………………………….. 231 x Blueprint in Pediatric Endocrinology CNS Tumors …………………………………………………………………… 232 Craniopharnygioma …………………………………………………………...... 232 Cranial irradiation ……………………………………………………………… 233 Growth velocity………………………………………………………………… 236 Laboratory evaluation of short stature………………………………………...... 238 Subsequent tests
Recommended publications
  • A Case of Acute Sheehan's Syndrome and Literature Review: a Rare but Life

    A Case of Acute Sheehan's Syndrome and Literature Review: a Rare but Life

    Matsuzaki et al. BMC Pregnancy and Childbirth (2017) 17:188 DOI 10.1186/s12884-017-1380-y CASEREPORT Open Access A case of acute Sheehan’s syndrome and literature review: a rare but life-threatening complication of postpartum hemorrhage Shinya Matsuzaki* , Masayuki Endo, Yutaka Ueda, Kazuya Mimura, Aiko Kakigano, Tomomi Egawa-Takata, Keiichi Kumasawa, Kiyoshi Yoshino and Tadashi Kimura Abstract Background: Sheehan’s syndrome occurs because of severe postpartum hemorrhage causing ischemic pituitary necrosis. Sheehan’s syndrome is a well-known condition that is generally diagnosed several years postpartum. However, acute Sheehan’s syndrome is rare, and clinicians have little exposure to it. It can be life-threatening. There have been no reviews of acute Sheehan’s syndrome and no reports of successful pregnancies after acute Sheehan’s syndrome. We present such a case, and to understand this rare condition, we have reviewed and discussed the literature pertaining to it. An electronic search for acute Sheehan’s syndrome in the literature from January 1990 and May 2014 was performed. Case presentation: A 27-year-old woman had massive postpartum hemorrhage (approximately 5000 mL) at her first delivery due to atonic bleeding. She was transfused and treated with uterine embolization, which successfully stopped the bleeding. The postpartum period was uncomplicated through day 7 following the hemorrhage. However, on day 8, the patient had sudden onset of seizures and subsequently became comatose. Laboratory results revealed hypothyroidism, hypoglycemia, hypoprolactinemia, and adrenal insufficiency. Thus, the patient was diagnosed with acute Sheehan’s syndrome. Following treatment with thyroxine and hydrocortisone, her condition improved, and she was discharged on day 24.
  • Abstracts from the 9Th Biennial Scientific Meeting of The

    Abstracts from the 9Th Biennial Scientific Meeting of The

    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
  • Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A

    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A

    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in a novel member of the chromodomain gene family cause CHARGE syndrome. L.E.L.M. Vissers1, C.M.A. van Ravenswaaij1, R. Admiraal2, J.A. Hurst3, B.B.A. de Vries1, I.M. Janssen1, W.A. van der Vliet1, E.H.L.P.G. Huys1, P.J. de Jong4, B.C.J. Hamel1, E.F.P.M. Schoenmakers1, H.G. Brunner1, A. Geurts van Kessel1, J.A. Veltman1. 1) Dept Human Genetics, UMC Nijmegen, Nijmegen, Netherlands; 2) Dept Otorhinolaryngology, UMC Nijmegen, Nijmegen, Netherlands; 3) Dept Clinical Genetics, The Churchill Hospital, Oxford, United Kingdom; 4) Children's Hospital Oakland Research Institute, BACPAC Resources, Oakland, CA. CHARGE association denotes the non-random occurrence of ocular coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear anomalies and deafness (OMIM #214800). Almost all patients with CHARGE association are sporadic and its cause was unknown. We and others hypothesized that CHARGE association is due to a genomic microdeletion or to a mutation in a gene affecting early embryonic development. In this study array- based comparative genomic hybridization (array CGH) was used to screen patients with CHARGE association for submicroscopic DNA copy number alterations. De novo overlapping microdeletions in 8q12 were identified in two patients on a genome-wide 1 Mb resolution BAC array. A 2.3 Mb region of deletion overlap was defined using a tiling resolution chromosome 8 microarray. Sequence analysis of genes residing within this critical region revealed mutations in the CHD7 gene in 10 of the 17 CHARGE patients without microdeletions, including 7 heterozygous stop-codon mutations.
  • Shh/Gli Signaling in Anterior Pituitary

    Shh/Gli Signaling in Anterior Pituitary

    SHH/GLI SIGNALING IN ANTERIOR PITUITARY AND VENTRAL TELENCEPHALON DEVELOPMENT by YIWEI WANG Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Department of Genetics CASE WESTERN RESERVE UNIVERSITY January, 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of _____________________________________________________ candidate for the ______________________degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. TABLE OF CONTENTS Table of Contents ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• i List of Figures ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• v List of Abbreviations •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• vii Acknowledgements •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• ix Abstract ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• x Chapter 1 Background and Significance ••••••••••••••••••••••••••••••••••••••••••••••••• 1 1.1 Introduction to the pituitary gland
  • Jcrpe-2018-0036.R1 Review Neonatal Hypopituitarism: Diagnosis and Treatment Approaches Running Short Title: Neonatal Hypopituita

    Jcrpe-2018-0036.R1 Review Neonatal Hypopituitarism: Diagnosis and Treatment Approaches Running Short Title: Neonatal Hypopituita

    Jcrpe-2018-0036.R1 Review Neonatal Hypopituitarism: Diagnosis and Treatment Approaches Running short title: Neonatal Hypopituitarism Selim Kurtoğlu1,2, Ahmet Özdemir1, Nihal Hatipoğlu2 1Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Neonatalogy 2Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology Corresponding author: Ahmet Özdemir MD, Department of Pediatrics, Division of Neonatalogy, Erciyes University Medical Faculty, Kayseri, Turkey E-mail: [email protected] Tel: 00-90-3522076666 Fax: 00-90-3524375825 Received: 01.02.2018 Accepted: 08.05.2018 What is already known on this topic? The pituitary gland is the central regulator of growth, metabolism, reproduction and homeostasis. Hypopituitarism is defined as a decreased release of hypophysis hormones, which may be caused by pituitary gland disease or hypothalamus disease. Clinical findings for neonatal hypopituitarism dependproof on causes and hormonal deficiency type and degree. If early diagnosis is not made, it may cause pituitary hormone deficiencies. What this study adds? We aim to contribute to the literature through a review of etiological factors, clinical findings, diagnoses and treatment approaches for neonatal hypopituitarism. We also aim to increase awareness of neonatal hypopituitarism. We also want to emphasize the importance of early recognition. Abstract Hypopituitarism is defined as a decreased release of hypophysis hormones, which may be caused by pituitary gland disease or hypothalamus disease. Clinical findings for neonatal hypopituitarism depend on causes and hormonal deficiency type and degree. Patients may be asymptomatic or may demonstrate non-specific symptoms, but may still be under risk for development of hypophysis hormone deficiency with time. Anamnesis, physical examination, endocrinological, radiological and genetic evaluations are all important for early diagnosis and treatment.
  • A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255ter) in IGSF1 Gene

    A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255ter) in IGSF1 Gene

    Türkkahraman D et al. A Novel Variant in IGSF1 Gene CASE REPORT DO I: 10.4274/jcrpe.galenos.2020.2020.0149 J Clin Res Pediatr Endocrinol 2021;13(3):353-357 A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255Ter) in IGSF1 Gene Doğa Türkkahraman1, Nimet Karataş Torun2, Nadide Cemre Randa3 1University of Health Sciences Turkey, Antalya Training and Research Hospital, Clinic of Pediatric Endocrinology, Antalya, Turkey 2University of Healty Sciences Turkey, Antalya Training and Research Hospital, Clinic of Pediatrics, Antalya, Turkey 3University of Healty Sciences Turkey, Antalya Training and Research Hospital, Clinic of Medical Genetics, Antalya, Turkey What is already known on this topic? Mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene that mainly regulates pituitary thyrotrope function lead to X-linked hypothyroidism characterized by congenital hypothyroidism of central origin and testicular enlargement. The clinical features associated with IGSF1 mutations are variable, but prolactin and/or growth hormone deficiency, and discordance between timing of testicular growth and rise of serum testosterone levels could be seen. What this study adds? Genetic analysis revealed a novel c.3763C>T variant in the IGSF1 gene. To our knowledge, this is the first reported case of IGSF1 deficiency from Turkey. Additionally, as in our case, early testicular enlargement but delayed testosterone rise should be evaluated in all boys with central hypothyroidism, as macro-orchidism is usually seen in adulthood. Abstract Loss-of-function mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene cause X-linked central hypothyroidism, and therefore its mutation affects mainly males. Central hypothyroidism in males is the hallmark of the disorder, however some patients additionally present with hypoprolactinemia, transient and partial growth hormone deficiency, early/normal timing of testicular enlargement but delayed testosterone rise in puberty, and adult macro-orchidism.
  • Childhood Growth and Puberty Delay Disorders

    Childhood Growth and Puberty Delay Disorders

    Childhood Growth and Puberty Delay Disorders MAJ Craig Barstow, MD ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations. The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP. 1 DISCLOSURE It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
  • Incorrect Unit of Measure

    Incorrect Unit of Measure

    We agree with Berman that there may often be honest dif- (2) make the rationale public, and (3) provide opportunities for ferences of opinion among informed experts about the value of clinicians and members to appeal policies and specific deci- new treatments. As stated in our article, our study cannot sions.1 However, even in the outstanding programs we were establish whether current practices are right or wrong. How- privileged to study in our research on policymaking, we and ever, the wide gap between the recommendations of physi- the program leaders agreed there was room for significant cians and the approvals of insurers in the cases under study improvement. underscores a potentially far-reaching problem in the US Ms Tesch’s letter on behalf of the Turner’s Syndrome Soci- health care system. We believe that insurers often make very ety provides an example of well-conceived advocacy. The fact careful and fair analyses of information in arriving at coverage that GH has been recognized by the Food and Drug Admin- decisions.1 Nevertheless, greater dialogue between insurers istration as effective in the treatment of Turner syndrome and physicians is needed to minimize discrepancies in cover- puts a burden of explanation onto an insurer who chooses not age and to provide optimal patient care. to cover it. In asking whether decisions to deny coverage re- Dr Yaes asks about consensus among physicians for the flect “reasonable cost-benefit analysis or an inappropriate de- cases studied and about the value of a treatment such as GH, nial of care,” Tesch raises the key policy question in useful which is used for a non–life-threatening condition.
  • Клиничкская Патофизиология: Осоновы=Clinical Pathophysiology

    Клиничкская Патофизиология: Осоновы=Clinical Pathophysiology

    Министерство здравоохранения Республики Беларусь УО «Витебский государственный ордена Дружбы народов медицинский университет» Беляева Л.Е. КЛИНИЧЕСКАЯ ПАТОФИЗИОЛОГИЯ: ОСНОВЫ Belyaeva L.Eu. CLINICAL PATHOPHYSIOLOGY: THE ESSENTIALS Пособие Рекомендовано учебно-методическим объединением по высшему медицинскому, фармацевтическому образованию Республики Беларусь в качестве пособия для студентов учреждений высшего образования, обучающихся по специальности 1-79 01 01 «Лечебное дело» Витебск 2018 УДК 616-092=111(07) ББК 52я73+54.1я73 B 41 Рекомендовано к изданию Центральным учебно-методическим советом ВГМУ в качестве пособия (25.10.2017 протокол № 9) Автор: Л.Е. Беляева Рецензенты: д.м.н., проф., чл.-корр. НАН Б, зав. каф. патологической физиологии Белорусского государственного медицинского университета Ф.И. Висмонт; кафедра патологической физиологии Гродненского государственного медицинского университета (зав. каф. – проф. Н.Е. Максимович) B 41 Клиническая патофизиология: основы = Clinical pathophysiology: the essentials : пособие / Л.Е. Беляева. – Витебск : ВГМУ, 2018. – 355 с. ISBN 978-985-466-932-8 В издании рассматриваются вопросы патофизиологии заболеваний основных систем организма, а также обсуждаются патофизиологические основы диагностики, профилактики и лечения заболеваний человека. Предназначено для студентов 3 и 4 курсов, изучающих дисциплины «Патологическая физиология» и «Клиническая патологическая физиология» на английском языке. УДК 616-092=111(07) ББК 73+54.1я73 ISBN 978-985-466-932-8 Оформление. УО «Витебский государственный
  • Guideline for the Diagnosis and Treatment of Celiac

    Guideline for the Diagnosis and Treatment of Celiac

    JOBNAME: gas 40#1 2005 PAGE: 1 OUTPUT: Wed December 15 18:39:15 2004 lww/gas/84141/MPG157309 Prod #: MPG157309 MS #xxx Journal of Pediatric Gastroenterology and Nutrition 40:1–19 Ó January 2005 Lippincott Williams & Wilkins, Philadelphia Clinical Guideline Guideline for the Diagnosis and Treatment of Celiac Disease in Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition ABSTRACT The Committee examined the indications for testing, the value Celiac disease is an immune-mediated enteropathy caused by of serological tests, human leukocyte antigen (HLA) typing and a permanent sensitivity to gluten in genetically susceptible in- histopathology and the treatment and monitoring of children dividuals. It occurs in children and adolescents with gastroin- with celiac disease. It is recommended that children and ado- testinal symptoms, dermatitis herpetiformis, dental enamel lescents with symptoms of celiac disease or an increased risk defects, osteoporosis, short stature, delayed puberty and persis- for celiac disease have a blood test for antibody to tissue tent iron deficiency anemia and in asymptomatic individuals transglutaminase (TTG), that those with an elevated TTG be with type 1 diabetes, Down syndrome, Turner syndrome, Williams referred to a pediatric gastroenterologist for an intestinal biopsy syndrome, selective immunoglobulin (Ig)A deficiency and first and that those with the characteristics of celiac disease on degree relatives of individuals with celiac disease. The Celiac intestinal histopathology be treated with a strict gluten-free Disease Guideline Committee of the North American Society diet. This document represents the official recommendations of for Pediatric Gastroenterology, Hepatology and Nutrition has the North American Society for Pediatric Gastroenterology, formulated a clinical practice guideline for the diagnosis and Hepatology and Nutrition on the diagnosis and treatment of treatment of pediatric celiac disease based on an integration of celiac disease in children and adolescents.
  • BIOL 252-005-Ahmed-Vawda.Pdf

    BIOL 252-005-Ahmed-Vawda.Pdf

    School of Arts & Science BIOLOGY DEPARTMENT BIOL 252-1 to 6 Pathophysiology for Nursing 1 2007F COURSE OUTLINE The Approved Course Description is available on the web @ Ω Please note: this outline will be electronically stored for five (5) years only. It is strongly recommended students keep this outline for your records. 1. Instructor Information (a) Instructor: Ahmed Vawda, (Patty Foster, Darlaine Jantzen) (b) Office Hours: M 12.30-2.30, W 11.30-12.30, 1.30-2.30, F 9.30-10.30 (c) Location: F342D (d) Phone: 370-3479 Alternative Phone: (e) Email: [email protected] (f) Website: 2. Intended Learning Outcomes (No changes are to be made to this section, unless the Approved Course Description has been forwarded through EDCO for approval.) Upon completion of this course the student will be able to: 1. Explain basic concepts of disease processes. 2. With reference to endocrine, cardiovascular, and respiratory disorders, explain how and why normal physiology is altered in the pathogenesis of specific diseases. 3. Correlate disease with treatment and nursing management in one’s patients. 4. Explain in lay terms the major features of a patient’s disease to the patient. 3. Required Materials (a) Texts REQUIRED TEXTBOOKS Porth, C.M. (2005). Pathophysiology. Concepts of Altered Health States. 7th ed. Lippincott Williams & Wilkins. Day, R.A., Paul, P., Williams, B., Smeltzer, S.C. and Bare, B. (2007). Brunner & Suddarth’s Textbook of Medical-Surgical Nursing, First Canadian Edition. Lippincott Williams & Wilkins. 1 Lilley, L., Harrington, S., Snyder, J. and Swart, C. (2007). Pharmacology and the Nursing Process in Canada.
  • Delayed Adrenarche May Be an Additional Feature of Immunoglobulin Super Family Member 1 Deficiency Syndrome

    Delayed Adrenarche May Be an Additional Feature of Immunoglobulin Super Family Member 1 Deficiency Syndrome

    J Clin Res Pediatr Endocrinol 2016;8(1):86-91 DO I: 10.4274/jcrpe.2512 Case Report Delayed Adrenarche may be an Additional Feature of Immunoglobulin Super Family Member 1 Deficiency Syndrome Severine Van Hulle1, Margarita Craen1, Bert Callewaert2, Sjoerd Joustra3, Wilma Oostdijk4, Monique Losekoot5, Jan Maarten Wit4, Marc Olivier Turgeon6, Daniel J. Bernard6, Jean De Schepper1 1University Hospital Gent, Department of Pediatrics, Gent, Belgium 2University Hospital Gent, Department of Medical Genetics, Gent, Belgium 3Leiden University Medical Center, Department of Internal Medicine, Division of Endocrinology, Leiden, Netherlands 4Leiden University Medical Center, Department of Pediatrics, Leiden, Netherlands 5Leiden University Medical Center, Department of Clinical Genetics, Leiden, Netherlands 6McGill University, Department of Pharmacology and Therapeutics, Quebec, Canada ABS TRACT Immunoglobulin super family member 1 (IGSF1) deficiency syndrome is characterized by central hypothyroidism, delayed surge in testosterone during puberty, macro-orchidism, and in some cases, hypoprolactinemia and/ or transient growth hormone (GH) deficiency. Our patient was a 19-year-old male adolescent who had been treated since the age of 9 years with GH and thyroxine for an idiopathic combined GH, thyroid-stimulating hormone (TSH), and prolactin (PRL) deficiency. His GH deficiency proved to be transient, but deficiencies of TSH and PRL persisted, and he had developed macro-orchidism since the end of puberty. Brain magnetic resonance imaging and PROP1 and POU1F1 sequencing were normal. A disharmonious puberty (delayed genital and WHAT IS ALREADY KNOWN ON THIS TOPIC? pubic hair development, bone maturation, and pubertal growth spurt, despite normal testicular growth) was observed as well as a delayed adrenarche, as Loss of function of the immunoglobulin super family member reflected by very low dehydroepiandrosterone sulfate and delayed pubarche.